Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 15.50M P/E - EPS this Y 75.30% Ern Qtrly Grth -
Income -13.51M Forward P/E -1.51 EPS next Y 73.20% 50D Avg Chg 15.00%
Sales 35.24M PEG - EPS past 5Y - 200D Avg Chg -21.00%
Dividend N/A Price/Book 0.93 EPS next 5Y - 52W High Chg -63.00%
Recommedations 2.00 Quick Ratio 0.85 Shares Outstanding 5.54M 52W Low Chg 57.00%
Insider Own 32.06% ROA -40.24% Shares Float 2.62M Beta 0.47
Inst Own 35.64% ROE -149.41% Shares Shorted/Prior 134.36K/105.54K Price 11.61
Gross Margin 47.74% Profit Margin -38.34% Avg. Volume 24,828 Target Price 11.50
Oper. Margin -64.69% Earnings Date Nov 9 Volume 2,832 Change -2.11%
About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Biofrontera Inc. News
12/23/24 Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
12/03/24 Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
11/22/24 Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
11/15/24 Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...
11/13/24 Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates
11/13/24 Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
11/01/24 Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
10/31/24 Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
10/23/24 Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc
10/14/24 Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
10/09/24 Biofrontera Inc (BFRI) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
10/07/24 FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
09:45 AM Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
08/17/24 Biofrontera Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
08/14/24 Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
08/09/24 Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
07/12/24 When Will Biofrontera Inc. (NASDAQ:BFRI) Become Profitable?
06/24/24 Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
05/15/24 Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
05/06/24 Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024